Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 5071 AL 5085

Endogenous antioxidants predicted outcome and increased after treatment: A benzoate dose-finding, randomized, double-blind, placebo-controlled trial for Alzheimer's disease

Lane HY, Wang SH, Lin CH.

Psychiatry Clin Neurosci. 2023 Feb;77(2):102-109. doi: 10.1111/pcn.13504. Epub 2022 Nov 24.

Elevated Cortical Tau Positron Emission Tomography Binding in Misery Perfusion: Novel, Puzzling, and Heuristic

Baron JC.

Stroke. 2022 Dec;53(12):e504-e506. doi: 10.1161/STROKEAHA.122.041406. Epub 2022 Nov 7.

Menopause and development of Alzheimer's disease: Roles of neural glucose metabolism and Wnt signaling

Villaseca P, Cisternas P, Inestrosa NC.

Front Endocrinol (Lausanne). 2022 Oct 19;13:1021796. doi: 10.3389/fendo.2022.1021796. eCollection 2022.

N-glycan branching enzymes involved in cancer, Alzheimer's disease and COPD and future perspectives

Taniguchi N, Ohkawa Y, Maeda K, Kanto N, Johnson EL, Harada Y.

Biochem Biophys Res Commun. 2022 Dec 10;633:68-71. doi: 10.1016/j.bbrc.2022.09.027. Epub 2022 Sep 10.

Alzheimer's disease - Where do we go from here?

Bezprozvanny I.

Biochem Biophys Res Commun. 2022 Dec 10;633:72-76. doi: 10.1016/j.bbrc.2022.08.075.

Thirty years of SET/TAF1β/I2PP2A: from the identification of the biological functions to its implications in cancer and Alzheimer's disease

Di Mambro A, Esposito MT.

Biosci Rep. 2022 Nov 30;42(11):BSR20221280. doi: 10.1042/BSR20221280.

Rational design of photoactivatable metal complexes to target and modulate amyloid-β peptides

Kwak J, Woo J, Park S, Lim MH.

J Inorg Biochem. 2023 Jan;238:112053. doi: 10.1016/j.jinorgbio.2022.112053. Epub 2022 Oct 28.

Plasmalogens inhibit neuroinflammation and promote cognitive function

Hossain MS, Mawatari S, Fujino T.

Brain Res Bull. 2023 Jan;192:56-61. doi: 10.1016/j.brainresbull.2022.11.005. Epub 2022 Nov 5.

ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies

Raulin AC, Doss SV, Trottier ZA, Ikezu TC, Bu G, Liu CC.

Mol Neurodegener. 2022 Nov 8;17(1):72. doi: 10.1186/s13024-022-00574-4.

Emerging roles of innate and adaptive immunity in Alzheimer's disease

Chen X, Holtzman DM.

Immunity. 2022 Dec 13;55(12):2236-2254. doi: 10.1016/j.immuni.2022.10.016. Epub 2022 Nov 8.

Marine Sources of DHA-Rich Phospholipids with Anti-Alzheimer Effect

Ferreira I, Rauter AP, Bandarra NM.

Mar Drugs. 2022 Oct 25;20(11):662. doi: 10.3390/md20110662.

Opportunities and challenges for the development of M(1) muscarinic receptor positive allosteric modulators in the treatment for neurocognitive deficits

Nguyen HTM, van der Westhuizen ET, Langmead CJ, Tobin AB, Sexton PM, Christopoulos A, Valant C.

Br J Pharmacol. 2024 Jul;181(14):2114-2142. doi: 10.1111/bph.15982. Epub 2022 Dec 4.

Hope on the horizon for Alzheimer's disease treatment?

The Lancet Healthy Longevity.

Lancet Healthy Longev. 2022 Nov;3(11):e722. doi: 10.1016/S2666-7568(22)00251-3.

Plasma Exchange in Alzheimer's Disease

Rohrer L, Yunce M, Montine TJ, Shan H.

Transfus Med Rev. 2023 Jan;37(1):10-15. doi: 10.1016/j.tmrv.2022.09.005. Epub 2022 Oct 3.

Empagliflozin Induced Ketosis, Upregulated IGF-1/Insulin Receptors and the Canonical Insulin Signaling Pathway in Neurons, and Decreased the Excitatory Neurotransmitter Glutamate in the Brain of Non-Diabetics

Avgerinos KI, Mullins RJ, Vreones M, Mustapic M, Chen Q, Melvin D, Kapogiannis D, Egan JM.

Cells. 2022 Oct 25;11(21):3372. doi: 10.3390/cells11213372.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias